These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
Nevada
|
27-2767540
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification Number)
|
|
1941 Ramrod Avenue, Suite #100
Henderson, Nevada 89014
|
89014
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Large accelerated filer
¨
|
Accelerated filer
¨
|
Non-accelerated filer
¨
|
Smaller reporting company
x
|
|
(Do not check if a smaller
reporting company)
|
|
Page
|
||
|
PART I. FINANCIAL INFORMATION
|
||
|
Item 1.
|
Financial Statements:
|
|
|
Condensed Balance Sheets as of June 30, 2011 (unaudited) and September 30, 2010
|
3
|
|
|
Condensed Statements of Operations for the three and nine months ended June 30, 2011
and 2010 (unaudited)
|
4
|
|
|
Condensed Statements of Cash Flows for the nine months ended June 30, 2011
and 2010 (unaudited)
|
5
|
|
|
Notes to Interim Condensed Financial Statements (unaudited)
|
6
|
|
|
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
16
|
|
Item 3.
|
Quantitative and Qualitative Disclosures about Market Risk
|
22
|
|
Item 4.
|
Controls and Procedures
|
22
|
|
PART II. OTHER INFORMATION
|
23
|
|
|
Item 1.
|
Legal Proceedings
|
23
|
|
Item 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds
|
23
|
|
Item 3.
|
Defaults Upon Senior Securities
|
23
|
|
Item 4.
|
(Removed and Reserved)
|
23
|
|
Item 5.
|
Other Information
|
23
|
|
Item 6.
|
Exhibits
|
23
|
|
SIGNATURES
|
23
|
|
|
June 30,
|
||||||||
|
2011
|
September 30,
|
|||||||
|
(unaudited)
|
2010
|
|||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash
|
$ | 482,077 | $ | 439,385 | ||||
|
Inventories, net
|
103,085 | 206 | ||||||
|
Prepaid expenses and other current assets
|
56,906 | 20,779 | ||||||
|
Total current assets
|
642,068 | 460,370 | ||||||
|
Equipment and tooling
, net
|
157,683 | 8,091 | ||||||
|
Patents and trademarks
, net
|
150,357 | 175,726 | ||||||
|
Total assets
|
$ | 950,108 | $ | 644,187 | ||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$ | 68,610 | $ | 147,670 | ||||
|
Accrued liabilities
|
178,578 | 27,307 | ||||||
|
Subordinated notes payable, net of discount
of $3,312 and $263,272, respectively
|
26,688 | 436,728 | ||||||
|
Total current liabilities
|
273,876 | 611,705 | ||||||
|
Commitments and contingencies (Note 9)
|
||||||||
|
Stockholders' equity:
|
||||||||
|
Preferred stock, $0.001 par value, authorized
1,000,000 shares, none issued and outstanding
|
- | - | ||||||
|
Common stock, $0.001 par value, authorized
50,000,000 shares, 19,117,027 and 15,306,064 shares issued and outstanding, respectively
|
19,117 | 15,306 | ||||||
|
Additional paid-in capital
|
2,529,087 | 703,127 | ||||||
|
Accumulated deficit
|
(1,871,972 | ) | (685,951 | ) | ||||
|
Total stockholders' equity
|
676,232 | 32,482 | ||||||
|
Total liabilities and stockholders' equity
|
$ | 950,108 | $ | 644,187 | ||||
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
June 30,
|
June 30,
|
|||||||||||||||
|
2011
|
2010
|
2011
|
2010
|
|||||||||||||
|
Revenues:
|
||||||||||||||||
|
Product sales
|
$ | - | $ | 167,224 | $ | - | $ | 512,369 | ||||||||
|
Other revenue
|
1,844 | 7,657 | 1,844 | 7,709 | ||||||||||||
|
Total revenues
|
1,844 | 174,881 | 1,844 | 520,078 | ||||||||||||
|
Cost of revenues
|
- | 149,907 | - | 441,403 | ||||||||||||
|
Gross profit
|
1,844 | 24,974 | 1,844 | 78,675 | ||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Selling, general and administrative
|
146,867 | 63,214 | 424,202 | 215,348 | ||||||||||||
|
Research and development
|
182,015 | 16,762 | 432,177 | 49,906 | ||||||||||||
|
Patent impairment
|
- | 18,005 | 28,616 | 40,301 | ||||||||||||
|
Total operating expenses
|
328,882 | 97,981 | 884,995 | 305,555 | ||||||||||||
|
Loss from operations
|
(327,038 | ) | (73,007 | ) | (883,151 | ) | (226,880 | ) | ||||||||
|
Other income (expense):
|
||||||||||||||||
|
Interest and note discount amortization
|
(158,712 | ) | - | (304,568 | ) | - | ||||||||||
|
Other
|
982 | - | 1,698 | - | ||||||||||||
| (157,730 | ) | - | (302,870 | ) | - | |||||||||||
|
Net loss
|
$ | (484,768 | ) | $ | (73,007 | ) | $ | (1,186,021 | ) | $ | (226,880 | ) | ||||
|
|
||||||||||||||||
|
Loss per basic and diluted common share
|
$ | (0.03 | ) | $ | (0.00 | ) | $ | (0.07 | ) | $ | (0.01 | ) | ||||
|
Weighted average shares used to compute net loss per basic and diluted common share
|
17,306,064 | 15,306,064 | 16,243,793 | 15,306,064 | ||||||||||||
|
Nine Months Ended
|
||||||||
|
June 30,
|
||||||||
|
2011
|
2010
|
|||||||
|
|
||||||||
|
Cash Flows From Operating Activities:
|
||||||||
|
Net loss
|
$ | (1,186,021 | ) | $ | (226,880 | ) | ||
|
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
|
||||||||
|
Depreciation and amortization
|
36,574 | 49,906 | ||||||
|
Debt discount and deferred financing cost amortization
|
262,683 | - | ||||||
|
Non-cash interest expense
|
37,400 | - | ||||||
|
Warranty provision
|
- | 16,462 | ||||||
|
Inventory obsolescence
|
(22,872 | ) | (26,159 | ) | ||||
|
Share-based compensation
|
145,651 | 4,971 | ||||||
|
Impairment of patents
|
28,616 | 40,301 | ||||||
|
Changes in assets and liabilities:
|
||||||||
|
Accounts receivable
|
- | (49,803 | ) | |||||
|
Prepaid expenses and other current assets
|
(38,576 | ) | - | |||||
|
Inventories
|
(80,007 | ) | 338,584 | |||||
|
Accounts payable
|
(79,060 | ) | 1,245 | |||||
|
Accrued liabilities
|
151,271 | (33,164 | ) | |||||
|
Net cash (used in) provided by operating activities
|
(744,341 | ) | 115,463 | |||||
|
Cash Flows From Investing Activities:
|
||||||||
|
Capital expenditures for equipment and tooling
|
(136,642 | ) | - | |||||
|
Patent costs paid
|
(32,771 | ) | (10,051 | ) | ||||
|
Net cash used in investing activities
|
(169,413 | ) | (10,051 | ) | ||||
|
Cash Flows From Financing Activities:
|
||||||||
|
Proceeds from sale of common stock and warrants
|
1,000,000 | - | ||||||
|
Offering costs paid
|
(43,554 | ) | - | |||||
|
Net change in investment from LRAD Corporation
|
- | (105,412 | ) | |||||
|
Net cash provided by (used in) financing activities
|
956,446 | (105,412 | ) | |||||
|
Net increase in cash and cash equivalents
|
42,692 | - | ||||||
|
Cash and cash equivalents, beginning of period
|
439,385 | - | ||||||
|
Cash and cash equivalents, end of period
|
$ | 482,077 | $ | - | ||||
|
Supplemental Disclosure of Non-Cash Investing and Financing Information:
|
||||||||
|
Purchase of tooling through issuance of stock options
|
$ | 20,000 | $ | - | ||||
|
Issuance of common stock upon warrant exercise in exchange for reduction in subordinated notes
|
$ | 420,000 | $ | - | ||||
|
Issuance of common stock in exchange for reduction of suborinated notes
|
$ | 250,000 | $ | - | ||||
|
June 30,
|
September 30,
|
|||||||
|
2011
|
2010
|
|||||||
|
Finished goods
|
$ | 7,492 | $ | - | ||||
|
Work in process
|
39,289 | - | ||||||
|
Raw materials
|
184,859 | 151,633 | ||||||
| 231,640 | 151,633 | |||||||
|
Reserve for obsolescence
|
(128,555 | ) | (151,427 | ) | ||||
| $ | 103,085 | $ | 206 | |||||
|
June 30,
|
September 30,
|
|||||||
|
2011
|
2010
|
|||||||
|
Equipment
|
$ | 142,251 | $ | 44,369 | ||||
|
Tooling
|
124,299 | 65,539 | ||||||
| 266,550 | 109,908 | |||||||
|
Accumulated deprcciation
|
(108,867 | ) | (101,817 | ) | ||||
| $ | 157,683 | $ | 8,091 | |||||
|
June 30,
|
September 30,
|
|||||||
|
2011
|
2010
|
|||||||
|
Patents
|
$ | 189,784 | $ | 127,771 | ||||
|
Defensive patents
|
151,317 | 222,017 | ||||||
|
Trademarks
|
6,292 | 6,292 | ||||||
| 347,393 | 356,080 | |||||||
|
Accumulated amortization
|
(197,036 | ) | (180,354 | ) | ||||
| $ | 150,357 | $ | 175,726 | |||||
|
Estimated
|
|||
|
Amortization
|
|||
|
Fiscal Years Ending September 30,
|
Expense
|
||
|
2011 (3 months remaining)
|
8,918
|
||
|
2012
|
35,671
|
||
|
2013
|
27,141
|
||
|
2014
|
24,798
|
||
|
2015
|
15,793
|
||
|
Thereafter
|
38,036
|
||
|
June 30,
|
September 30,
|
|||||||
|
2011
|
2010
|
|||||||
|
Accrued officer compensation
|
$ | 168,300 | $ | - | ||||
|
Accrued interest
|
4,521 | 307 | ||||||
|
Other
|
5,757 | 27,000 | ||||||
| $ | 178,578 | $ | 27,307 | |||||
|
Nine Months Ended
|
||||
|
June 30,
|
||||
|
|
2011
|
|||
|
Volatility
|
|
100%
|
||
|
Risk-free interest rate
|
|
1.16%
|
||
|
Forfeiture rate
|
|
0.00%
|
||
|
Dividend yield
|
0.00%
|
|||
|
Expected life in years
|
4.75
|
|||
|
Weighted average fair value of options granted
|
$0.25
|
|||
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
June 30,
|
June 30,
|
|||||||||||||||
|
2011
|
2010
|
2011
|
2010
|
|||||||||||||
|
Cost of revenue
|
$ | - | $ | - | $ | - | $ | 388 | ||||||||
|
Selling, general and administrative
|
24,682 | 589 | 67,881 | 4,583 | ||||||||||||
|
Research and development
|
30,654 | - | 77,770 | - | ||||||||||||
| $ | 55,336 | $ | 589 | $ | 145,651 | $ | 4,971 | |||||||||
|
Number
of Shares
|
Weighted Average
Exercise Price
|
Aggregate
Intrinsic Value (2)
|
||||||||||
|
Outstanding October 1, 2010
|
- | - |
|
|||||||||
|
Granted
|
1,700,000 | $ | 0.34 |
|
||||||||
|
Canceled/expired
|
- | - |
|
|||||||||
|
Exercised
|
- | - |
|
|||||||||
|
Outstanding June 30, 2011 (1)
|
1,700,000 | $ | 0.34 | $ | 984,050 | |||||||
|
Exercisable June 30, 2011
|
635,000 | $ | 0.34 | $ | 370,400 | |||||||
|
|
(1)
|
Options outstanding are exercisable at prices ranging from $0.30 to $0.66 and expire in 2015 to 2016.
|
|
|
(2)
|
Aggregate intrinsic value is based on the closing price of our common stock on June 30, 2011 of $0.92.
|
|
Additional
|
Total
|
|||||||||||||||||||
|
Common Stock
|
Paid-In
|
Accumulated
|
Stockholders'
|
|||||||||||||||||
|
Shares
|
Amount
|
Capital
|
Deficit
|
Equity
|
||||||||||||||||
|
Balance at September 30, 2010
|
15,306,064 | $ | 15,306 | $ | 703,127 | $ | (685,951 | ) | $ | 32,482 | ||||||||||
|
Sale of common stock and warrants at $0.50 per share, net of offering costs of $43,554
|
2,000,000 | 2,000 | 954,446 | - | 956,446 | |||||||||||||||
|
Warrants exercised at $0.30 per share applied to pay subordinated notes
|
1,400,000 | 1,400 | 418,600 | - | 420,000 | |||||||||||||||
|
Common stock issued at $0.70 per share to pay subordinated notes
|
410,963 | 411 | 287,263 | - | 287,674 | |||||||||||||||
|
Share-based compensation expense
|
- | - | 145,651 | - | 145,651 | |||||||||||||||
|
Stock options issued for tooling costs
|
- | - | 20,000 | - | 20,000 | |||||||||||||||
|
Net loss for the period11
|
- | - | - | (1,186,021 | ) | (1,186,021 | ) | |||||||||||||
|
Balance at June 30, 2011
|
19,117,027 | $ | 19,117 | $ | 2,529,087 | $ | (1,871,972 | ) | $ | 676,232 | ||||||||||
|
Number
|
Average Purchase Price Per Share
|
|||||||
|
Shares purchasable under outstanding warrants at October 1, 2010
|
1,400,000 | $ | 0.30 | |||||
|
Stock purchase warrants issued
|
2,000,000 | $ | 0.75 | |||||
|
Stock purchase warrants exercised
|
(1,400,000 | ) | $ | 0.30 | ||||
|
Shares purchasable under outstanding warrants at June 30, 2011
|
2,000,000 | $ | 0.75 | |||||
|
Number of
|
Exercise Price
|
||||||||
|
Description
|
Common Shares
|
Per Share
|
Expiration Date
|
||||||
|
Stock Purchase Warrants
|
2,000,000 | $ | 0.75 |
February 22, 2016
|
|||||
|
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
|
|
·
|
revenue recognition;
|
|
|
·
|
estimates and allowances (primarily doubtful accounts and inventory and patent obsolescence and impairment);
|
|
|
·
|
share-based compensation expense;
|
|
|
·
|
income taxes; and
|
|
|
·
|
fair value measurements.
|
|
|
·
|
market acceptance of our products and our ability to grow revenues;
|
|
|
·
|
the costs, timing and outcome of production and regulatory compliance of our products;
|
|
|
·
|
the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our issued patents and defending any future intellectual property-related claims;
|
|
|
·
|
the costs and timing of additional product development and marketing efforts;
|
|
|
·
|
the costs, timing and outcome of any future warranty claims or litigation against us associated with any of our products; and
|
|
|
·
|
the timing and costs associated with any new financing.
|
|
Item 3.
|
Qualitative and Quantitative Disclosures about Market Risk
|
|
Item 4.
|
Controls and Procedures.
|
|
Item 1.
|
Legal Proceedings.
|
|
Item 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds.
|
|
Item 3.
|
Defaults Upon Senior Securities.
|
|
Item 4.
|
(Removed and Reserved)
|
|
Item 5.
|
Other Information.
|
|
Item 6.
|
Exhibits
|
|
31.1
|
Certification of Elwood G. Norris, Principal Executive Officer, pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
31.2
|
Certification of James A. Barnes, Principal Financial Officer, pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
32.1
|
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, executed by Elwood G. Norris, Principal Executive Officer and James A. Barnes, Principal Financial Officer.
|
| Extensible Business Reporting Language (XBRL) Exhibits* | |
|
101.INS
|
XBRL Instance Document*
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document*
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document*
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document*
|
|
101.LAB
|
XBRL Taxonomy Extension Labels Linkbase Document*
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document*
|
|
PARAMETRIC SOUND CORPORATION
|
||
|
Date: August 2, 2011
|
By:
|
/s/ JAMES A. BARNES
|
|
James A. Barnes, Chief Financial Officer, Treasurer and Secretary
|
||
|
(Principal Financial Officer)
|
||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|